{"Clinical Trial ID": "NCT00024102", "Intervention": ["INTERVENTION 1:", "Standard chemotherapy", "Patient/physicist choice:", "CMF: cyclophosphamide (100 mg/m^2 orally days 1-14)+ MTX (40 mg/m^2 orally days 1-8) + 5-FU (600 mg/m^2 orally days 1-8) repeated every 28 days for 6 cycles OR", "AC: Cyclophosphamide (600 mg/m^2 per IV on day 1)+ doxorubicin (60 mg/m^2 per IV on day 1) repeated every 21 days for 4 cycles", "INTERVENTION 2:", "- Capecitabine", "Capecitabine (2000 mg/m^2 in 2 doses 1 to 14 days) is repeated every 21 days for 6 cycles."], "Eligibility": ["* Patients with histologically confirmed female breast adenocarcinoma.", "TNM Internship by AJCC Cancer Staging Manual 6th Edition:", "T1-4 (Title > 1 cm), N0, M0 or T1-4, N1-3, M0", "Patients with bilateral and synchronous breast cancer are eligible as long as a primary tumour meets the above criteria.", "Patients with positive, negative or unknown HER2/neu disease are eligible for this trial.", "Patients whose tumours are HER2 positive by immunohistochemistry 3+ staining or demonstrating gene amplification by FISH will be eligible to receive trastuzumab, as indicated in the protocol.", "\u2022 Age 65 or over", "Performance status 0-2 (Common Toxicity Criteria).", "Prior treatment:", "Surgical resection -", "All tumours should be eliminated either by modified radical mastectomy or by lumpectomy. Patients should be registered 84 days after mastectomy or within 84 days after axillary dissection if the patient's most important breast surgery was a breast dispersal procedure.", "The treatment of axilla is at the discretion of the attending physician. There are no restrictions on eligibility based on the number of nodes removed.", "Mastectomy: There should be no evidence of gross or microscopic invasive tumours at the surgical resection margins noted in the final surgical or pathology reports for patients who have had a modified radical mastectomy. Patients with narrow margins (tumor < 1 mm margin) are eligible.", "A segmental mastectomy (lumpectomy): Although clear margins are preferable, SICD or SILC at the surgical resection margin will not make a patient who has undergone segmental mastectomy inadmissible to this study.", "No previous chemotherapy for this malignancy.", "Patients with a history of hypersensitivity to 5-FU or known dihydropyrimidine dehydrogenase (DDP) deficiency are not eligible to participate.", "Patients who have received tamoxifen or raloxifene for chemoprevention purposes (e.g., breast cancer prevention trial) or other indications (including previous breast cancer) are eligible for treatment. Treatment with tamoxifen or raloxifene should be discontinued before the patient is enrolled in this study.", "Initial laboratory data required:", "Granulocytes > 1500/\u03bcl", "Number of platelets 100 000/\u03bcl", "Calculation of creatinine clearance > 30 mL/min", "Total bilirubin LSN"], "Results": ["Performance measures:", "Survival rate without relapse at 2.4 years", "The percentage of participants who were alive and without relapse at the time of the analysis was counted as \"living without relapse\" at 2.4 years of age. Participants who had a first local recurrence, a first distant metastasis or the death of any cause were counted as \"relapsing, first occurrence.\" These rates were estimated using the Kaplan Meier method.", "Time limit: randomization to the date of the first event, or the last known date to be free of event if no event has been reported (up to 5 years)", "Results 1:", "Title of the arm/group: Standard chemotherapy", "Description of the arm/group:", "CMF: cyclophosphamide (100 mg/m^2 orally days 1-14)+ MTX (40 mg/m^2 orally days 1-8) + 5-FU (600 mg/m^2 orally days 1-8) repeated every 28 days for 6 cycles OR", "AC: Cyclophosphamide (600 mg/m^2 per IV on day 1)+ doxorubicin (60 mg/m^2 per IV on day 1) repeated every 21 days for 4 cycles", "Total number of participants analysed: 326", "Type of measurement: Number", "Unit of measure: percentage of participants Falling, first event: 11", "Living without relapse: 89", "Results 2:", "Title of the arm/group: Capecitabine", "Description of the arm/group: Capecitabine (2000 mg/m^2 in 2 doses 1-14 days) repeated every 21 days for 6 cycles.", "Total number of participants analysed: 307", "Type of measurement: Number", "Unit of measure: percentage of participants Falling, first event: 20", "Living without relapse: 80"], "Adverse Events": ["Undesirable Events 1:", "Total: 15/131 (11.45%)", "Disseminate intravascular coagulation 1/131 (0.76 %)", "5/131 (3.82 per cent)", "Decreased haemoglobin 7/131 (5.34%)", "- Lymphatic 1/131 (0.76 per cent)", "- Transfusion: pRBC 0.131 (0.00 %)", "Superventricular arrhythmia 0.131 (0.00 %)", "1/131 (0.76 %)", "Ed. 0.131 (0.00 %)", "- Left ventricular failure 0.131 (0.00 %)", "Ischemia myocardial 1/131 (0.76 %)", "Adverse Events 2:", "Total: 17/181 (9.39 per cent)", "Disseminate intravascular coagulation 0/181 (0.00 %)", "Febrile neutropenia 1/181 (0.55%)", "Haemoglobin decrease 13/181 (7.18%)", "- Lymphatic 0/181 (0.00 %)", "Transfusion: pRBC 1/181 (0.55%)", "1/181 (0.55%)", "Cardiac disorders 0/181 (0.00 %)", "Ed. 0/181 (0.00 %)", "Left ventricular failure 1/181 (0.55%)", "Ischemic myocardium 0/181 (0.00 %)"]}